We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Medica 2024 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Noninvasive Cholesterol Testing Becomes Available to Public

By LabMedica International staff writers
Posted on 14 Jun 2011
Noninvasive cholesterol testing technology will be available to the public through a clinical reference laboratory testing for the first time.

PreVu is a noninvasive risk assessment technology that evaluates the additional risk a person may have for coronary artery disease (CAD) by conveniently and painlessly testing their skin cholesterol level.

High levels of skin cholesterol have been shown to be correlated to CAD as measured by stress test, angiography, coronary calcium, carotid intima-media thickness, inflammatory markers of vascular disease, previous heart attack incidents, and Framingham risk score.

Miraculins Inc. (Winnipeg, Canada), a medical diagnostic company focused on developing and commercializing diagnostic tests and risk assessment tools for unmet clinical needs, has signed a Letter of Intent with Gamma-Dynacare Medical Laboratories (Brampton, Canada), one of Canada's largest and medical laboratories, to introduce a laboratory processed format of its PreVu noninvasive cholesterol test technology.

Under the terms of the agreement, Gamma-Dynacare will be responsible for all costs related to the final development stages of the PreVu LP test as well as the development and implementation of an automated system to process the test at a centralized facility. Gamma-Dynacare will also provide logistical support for collection, transportation and results reporting utilizing Gamma's internal infrastructure, which handles tens of thousands of specimens daily, and delivers more than 40 million tests annually. As part of the agreement, Miraculins has awarded Gamma-Dynacare the exclusive rights to process all PreVu LP Tests sold in Canada.

The PreVu LP test noninvasively measures the amount of cholesterol that has been deposited in skin tissues by painlessly and rapidly collecting skin cells from the palm of the hand using a medical adhesive collection device, which would then be sealed and sent to a Gamma-Dynacare laboratory for processing. The sample collection process is easily self-performed, takes 15 sec. to conduct, and does not require fasting.

Related Links:

Miraculins Inc.
Gamma-Dynacare Medical Laboratories



New
Gold Member
ANA & ENA Screening Assays
ANA and ENA Assays
Automated Blood Typing System
IH-500 NEXT
New
Thyroxine ELISA
T4 ELISA
New
Anti-Secukinumab ELISA
LISA-TRACKER anti-Secukinumab

Latest Clinical Chem. News

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Integrated Chemistry and Immunoassay Analyzer with Extensive Assay Menu Offers Flexibility, Scalability and Data Commutability